{"id":"NCT04864834","sponsor":"Sandoz","briefTitle":"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration","officialTitle":"A 52-week Multicenter, Randomized, Double-masked, 2-arm Parallel Study to Compare Efficacy, Safety and Immunogenicity of SOK583A1 to Eylea®, Administered Intravitreally, in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-12","primaryCompletion":"2022-07-07","completion":"2023-05-10","firstPosted":"2021-04-29","resultsPosted":"2024-03-26","lastUpdate":"2024-03-26"},"enrollment":485,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Neovascular Age-related Macular Degeneration"],"interventions":[{"type":"BIOLOGICAL","name":"SOK583A1 (40 mg/mL)","otherNames":[]},{"type":"BIOLOGICAL","name":"Eylea EU (40 mg/mL)","otherNames":[]}],"arms":[{"label":"SOK583A1 (40 mg/mL)","type":"EXPERIMENTAL"},{"label":"Eylea EU (40 mg/mL)","type":"ACTIVE_COMPARATOR"}],"summary":"Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD.\n\nThe primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?","primaryOutcome":{"measure":"Best-Corrected Visual Acuity (BCVA) Will be Assessed Using the ETDRS Testing Charts at an Initial Distance of 4 Meters. The Change From Baseline in BCVA in Letters is Defined as Difference Between BCVA Score Between Week 8 and Baseline.","timeFrame":"Change from baseline in mean BCVA score at Week 8","effectByArm":[{"arm":"SOK583A1 (40 mg/mL)","deltaMin":6.5,"sd":8.98},{"arm":"Eylea EU (40 mg/mL)","deltaMin":6.8,"sd":7.46}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":102,"countries":["United States","Australia","Austria","Bulgaria","Czechia","France","Germany","Hungary","Israel","Japan","Latvia","Lithuania","Poland","Portugal","Slovakia","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":39,"n":244},"commonTop":["Neovascular age-related macular degeneration","COVID-19","Hypertension","Visual acuity reduced"]}}